Evidence map›Paper›PMID 29961171›Full record

ArticleInflammation2018

Curcumin Attenuates Airway Inflammation and Airway Remolding by Inhibiting NF-κB Signaling and COX-2 in Cigarette Smoke-Induced COPD Mice.

Jin Yuan, Renping Liu, Yaohui Ma, Zhaoqiang Zhang, Zehao Xie

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04687449 (Curcumin in Management of Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04687449 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Curcumin in Management of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial (C-COPD Trial)

TypeinterventionalSponsorDanbury HospitalRan2022 to 2023Enrolled120ConditionsCOPDArmsCurcumin therapy, Placebo, Standard care
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Natural Products for the Management of Asthma and COPD.Handbook of experimental pharmacology · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jin YuanMedical Experiment Education Department, Medical College of Nanchang University, No.1299, Xuefu Road, Honggutan District, Nanchang, 330031, Jiangxi Province, China.
Renping LiuMedical Experiment Education Department, Medical College of Nanchang University, No.1299, Xuefu Road, Honggutan District, Nanchang, 330031, Jiangxi Province, China. sirlrp@163.com.
Yaohui MaMedical Experiment Education Department, Medical College of Nanchang University, No.1299, Xuefu Road, Honggutan District, Nanchang, 330031, Jiangxi Province, China.
Zhaoqiang ZhangMedical Experiment Education Department, Medical College of Nanchang University, No.1299, Xuefu Road, Honggutan District, Nanchang, 330031, Jiangxi Province, China.
Zehao XieMedical Experiment Education Department, Medical College of Nanchang University, No.1299, Xuefu Road, Honggutan District, Nanchang, 330031, Jiangxi Province, China.

Funding

Department of Science and Technology Program Funds of Jiangxi Province No. 20151BAB205085
6 · The paper itself

Abstract

The purpose of this study is to evaluate the therapeutic effects of curcumin on airway inflammation using LPS and cigarette smoke (LC)-induced COPD murine models and LPS-stimulated human bronchial epithelial (BEAS-2B) cells. In this research, COPD murine models were established after challenged with LPS for 2 days and exposed to cigarette smoke for 35 days. Treatment with curcumin for 10 days distinctly alleviated airway inflammation and airway remolding in LC-induced COPD mice according to the lung H&E histopathological examination. The number of neutrophils and lymphocytes in broncho alveolar lavage fluid (BALF) was significantly decreased in curcumin+LC-treated group compared with the LC-induced mice. Additionally, curcumin inhibited BEAS-2B cells proliferation, which suggested the preventive effect of curcumin on progressive airway remolding and inflammatory response mediated by bronchial epithelial cells. Further investigation demonstrated an underlying molecular mechanism for the therapeutic effects of curcumin may rely on the inhibition of the degradation of IκBα and COX-2 expression in curcumin+LC-treated COPD mice and LPS-stimulated BEAS-2B cells. Overall, curcumin alleviates the airway inflammation and airway remolding, which is closely related to inhibit the BEAS-2B cells proliferation and suppress the activation of NF-κB and COX-2 expression. These findings indicate that curcumin may be a potential agent for the therapy of COPD.

Indexed as

Airway RemodelingAnimalsBronchiCell LineCurcuminCyclooxygenase 2Epithelial CellsHumansInflammationMiceNF-kappa BNF-KappaB Inhibitor alphaPulmonary Disease, Chronic ObstructiveSmokeTobacco ProductsCurcuminCyclooxygenase 2NF-kappa BNF-KappaB Inhibitor alphaSmokeCOPDCOX-2CurcuminInflammationNF-κB

Identifiers

PMID29961171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.